

# Scott L Pomeroy

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8187649/scott-l-pomeroy-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

66

papers

36,126

citations

40

h-index

92

g-index

92

ext. papers

47,236

ext. citations

15.2

avg, IF

6.26

L-index

| #  | Paper  | IF   | Citations |
|----|--|------|-----------|
| 66 | Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2005</b> , 102, 15545-50              | 11.5 | 24578     |
| 65 | Prediction of central nervous system embryonal tumour outcome based on gene expression. <i>Nature</i> , <b>2002</b> , 415, 436-42  | 50.4 | 1857      |
| 64 | Molecular subgroups of medulloblastoma: the current consensus. <i>Acta Neuropathologica</i> , <b>2012</b> , 123, 465-72  | 14.3 | 1167      |
| 63 | Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. <i>Acta Neuropathologica</i> , <b>2012</b> , 123, 473-84 | 14.3 | 678       |
| 62 | Dissecting the genomic complexity underlying medulloblastoma. <i>Nature</i> , <b>2012</b> , 488, 100-5   | 50.4 | 623       |
| 61 | Subgroup-specific structural variation across 1,000 medulloblastoma genomes. <i>Nature</i> , <b>2012</b> , 488, 49-56  | 50.4 | 596       |
| 60 | Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. <i>Nature</i> , <b>2012</b> , 488, 106-10  | 50.4 | 552       |
| 59 | Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. <i>Nature Genetics</i> , <b>2013</b> , 45, 927-32   | 36.3 | 550       |
| 58 | Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 1424-30   | 2.2  | 513       |
| 57 | The whole-genome landscape of medulloblastoma subtypes. <i>Nature</i> , <b>2017</b> , 547, 311-317   | 50.4 | 472       |
| 56 | Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothed inhibition. <i>Cancer Cell</i> , <b>2014</b> , 25, 393-405   | 24.3 | 469       |
| 55 | Medulloblastomics: the end of the beginning. <i>Nature Reviews Cancer</i> , <b>2012</b> , 12, 818-34   | 31.3 | 443       |
| 54 | Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. <i>Acta Neuropathologica</i> , <b>2016</b> , 131, 821-31   | 14.3 | 324       |
| 53 | Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2927-35   | 2.2  | 290       |
| 52 | Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. <i>Acta Neuropathologica</i> , <b>2012</b> , 123, 615-26   | 14.3 | 265       |
| 51 | Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. <i>Lancet Oncology</i> , <b>2013</b> , 14, 1200-7   | 21.7 | 226       |
| 50 | Medulloblastoma. <i>Nature Reviews Disease Primers</i> , <b>2019</b> , 5, 11   | 51.1 | 202       |

|    |   |      |     |
|----|---|------|-----|
| 49 | Cytogenetic prognostication within medulloblastoma subgroups. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 886-96  | 2.2  | 199 |
| 48 | SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation. <i>Nature Genetics</i> , <b>2017</b> , 49, 289-295  | 36.3 | 172 |
| 47 | Resolving medulloblastoma cellular architecture by single-cell genomics. <i>Nature</i> , <b>2019</b> , 572, 74-79   | 50.4 | 133 |
| 46 | Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma. <i>Acta Neuropathologica</i> , <b>2012</b> , 123, 539-52  | 14.3 | 132 |
| 45 | Conserved mechanisms across development and tumorigenesis revealed by a mouse development perspective of human cancers. <i>Genes and Development</i> , <b>2004</b> , 18, 629-40   | 12.6 | 129 |
| 44 | Focus on central nervous system neoplasia. <i>Cancer Cell</i> , <b>2002</b> , 1, 125-8  | 24.3 | 115 |
| 43 | The G protein $\beta$ subunit $G\beta$ is a tumor suppressor in Sonic hedgehog-driven medulloblastoma. <i>Nature Medicine</i> , <b>2014</b> , 20, 1035-42   | 50.5 | 82  |
| 42 | MB-103 DiSCoVeRiNg INNOVATIVE THERAPIES: COMBINING GENETICALLY ACCURATE DISEASE MODELS OF MEDULLOBLASTOMA WITH ADVANCED IN SILICO ANALYSIS TO IDENTIFY NOVEL THERAPEUTIC TARGETS. <i>Neuro-Oncology</i> , <b>2016</b> , 18, iii120.3-iii120 | 1    | 78  |
| 41 | MB-27 * PATHWAY ANALYSIS OF A HUMAN NEURAL STEM CELL MODEL OF AGGRESSIVE MEDULLOBLASTOMA REVEALS CKD INHIBITION AS A POTENTIAL THERAPEUTIC MODALITY. <i>Neuro-Oncology</i> , <b>2015</b> , 17, iii25-iii26                                  | 1    | 78  |
| 40 | PDTM-24. PINEOBLASTOMA SEGREGATES INTO MOLECULAR SUBTYPES WITH DISTINCT CLINICOPATHOLOGIC FEATURES: REPORT FROM THE RARE BRAIN TUMOUR CONSORTIUM. <i>Neuro-Oncology</i> , <b>2019</b> , 21, vi192-vi192                                     | 1    | 78  |
| 39 | PDTM-32. RESOLVING MEDULLOBLASTOMA CELLULAR ARCHITECTURE BY SINGLE-CELL GENOMICS. <i>Neuro-Oncology</i> , <b>2019</b> , 21, vi194-vi194   | 1    | 78  |
| 38 | EMBR-17. PINEOBLASTOMA SEGREGATES INTO MOLECULAR SUBTYPES WITH DISTINCT CLINICOPATHOLOGIC FEATURES: REPORT FROM THE RARE BRAIN TUMOR CONSORTIUM. <i>Neuro-Oncology</i> , <b>2018</b> , 20, i72-i73  | 1    | 78  |
| 37 | Medulloblastoma tumorigenesis diverges from cerebellar granule cell differentiation in patched heterozygous mice. <i>Developmental Biology</i> , <b>2003</b> , 263, 50-66   | 3.1  | 77  |
| 36 | Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups. <i>Cancer Cell</i> , <b>2018</b> , 34, 396-410.e8   | 24.3 | 74  |
| 35 | Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 994-8   | 2.2  | 70  |
| 34 | Circulating serpin tumor markers SCCA1 and SCCA2 are not actively secreted but reside in the cytosol of squamous carcinoma cells. <i>International Journal of Cancer</i> , <b>2000</b> , 89, 368-77   | 7.5  | 60  |
| 33 | Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 1415-23   | 2.2  | 58  |
| 32 | Single-Cell Transcriptomics in Medulloblastoma Reveals Tumor-Initiating Progenitors and Oncogenic Cascades during Tumorigenesis and Relapse. <i>Cancer Cell</i> , <b>2019</b> , 36, 302-318.e7  | 24.3 | 49  |

|    |   |      |    |
|----|---|------|----|
| 31 | Medulloblastoma: Molecular Classification-Based Personal Therapeutics. <i>Neurotherapeutics</i> , <b>2017</b> , 14, 265-273   | 6.4  | 47 |
| 30 | Identification of PATCHED mutations in medulloblastomas by direct sequencing. <i>Human Mutation</i> , <b>2000</b> , 16, 89-90   | 4.7  | 47 |
| 29 | Magnetic resonance imaging changes after stereotactic radiation therapy for childhood low grade astrocytoma. <i>Cancer</i> , <b>1996</b> , 78, 864-73   | 6.4  | 47 |
| 28 | DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 3903-14      | 12.9 | 43 |
| 27 | Incidence, risk factors, and longitudinal outcome of seizures in long-term survivors of pediatric brain tumors. <i>Epilepsia</i> , <b>2015</b> , 56, 1599-604   | 6.4  | 40 |
| 26 | WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. <i>Acta Neuropathologica Communications</i> , <b>2014</b> , 2, 174  | 7.3  | 32 |
| 25 | Rapid discrimination of pediatric brain tumors by mass spectrometry imaging. <i>Journal of Neuro-Oncology</i> , <b>2018</b> , 140, 269-279  | 4.8  | 29 |
| 24 | MicroRNA-1301 suppresses tumor cell migration and invasion by targeting the p53/UBE4B pathway in multiple human cancer cells. <i>Cancer Letters</i> , <b>2017</b> , 401, 20-32  | 9.9  | 28 |
| 23 | Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study. <i>Acta Neuropathologica</i> , <b>2020</b> , 139, 223-241                           | 14.3 | 28 |
| 22 | Neuralized1 causes apoptosis and downregulates Notch target genes in medulloblastoma. <i>Neuro-Oncology</i> , <b>2010</b> , 12, 1244-56   | 1    | 27 |
| 21 | Hedgehog-Gli pathway in medulloblastoma. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2154-6   | 2.2  | 27 |
| 20 | Defining the molecular landscape of ependymomas. <i>Cancer Cell</i> , <b>2015</b> , 27, 613-5   | 24.3 | 25 |
| 19 | Molecular biology of medulloblastoma therapy. <i>Pediatric Neurosurgery</i> , <b>2003</b> , 39, 299-304   | 0.9  | 23 |
| 18 | Neurotrophins in cerebellar granule cell development and medulloblastoma. <i>Journal of Neuro-Oncology</i> , <b>1997</b> , 35, 347-52   | 4.8  | 22 |
| 17 | The evolution of medulloblastoma therapy to personalized medicine. <i>F1000Research</i> , <b>2017</b> , 6, 490  | 3.6  | 21 |
| 16 | Posterior fossa ependymomas: a tale of two subtypes. <i>Cancer Cell</i> , <b>2011</b> , 20, 133-4   | 24.3 | 14 |
| 15 | Molecular genetics of pediatric central nervous system tumors. <i>Current Oncology Reports</i> , <b>2006</b> , 8, 423-96.3  |      | 13 |
| 14 | Children's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 2685-2697 | 2.2  | 12 |

|    |   |      |   |
|----|---|------|---|
| 13 | Postnatal addition of satellite cells to parasympathetic neurons. <i>Journal of Comparative Neurology</i> , <b>1996</b> , 375, 518-25   | 3.4  | 8 |
| 12 | Medulloblastoma biology in the post-genomic era. <i>Future Oncology</i> , <b>2012</b> , 8, 1597-604   | 3.6  | 6 |
| 11 | Brain cancer genomics and epigenomics. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2018</b> , 148, 785-797  | 3    | 4 |
| 10 | Epigenetics and survivorship in pediatric brain tumor patients. <i>Journal of Neuro-Oncology</i> , <b>2020</b> , 150, 77-83   | 4.8  | 3 |
| 9  | Neural development and the ontogeny of central nervous system tumors. <i>Neuron Glia Biology</i> , <b>2004</b> , 1, 127-33  |      | 3 |
| 8  | Loss of Consciousness in the Young Child. <i>Pediatric Cardiology</i> , <b>2021</b> , 42, 234-254   | 2.1  | 2 |
| 7  | Intellectual and developmental disabilities research centers: Fifty years of scientific accomplishments. <i>Annals of Neurology</i> , <b>2019</b> , 86, 332-343   | 9.4  | 1 |
| 6  | Microarray Analysis and Proteomic Approaches to Drug Development <b>2006</b> , 74-88  |      | 1 |
| 5  | TORC1/2 kinase inhibition depletes glutathione and synergizes with carboplatin to suppress the growth of MYC-driven medulloblastoma. <i>Cancer Letters</i> , <b>2021</b> , 504, 137-145                             | 9.9  | 1 |
| 4  | Tracking the Fate of Cells in Health and Disease. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 2494-2496   | 59.2 | 1 |
| 3  | Validation of a computational phenotype for finding patients eligible for genetic testing for pathogenic PTEN variants across three centers.. <i>Journal of Neurodevelopmental Disorders</i> , <b>2022</b> , 14, 24 | 4.6  | 0 |
| 2  | Neuro-oncology training for the child neurology resident. <i>Seminars in Pediatric Neurology</i> , <b>2011</b> , 18, 120-2.9  |      |   |
| 1  | SEQing to find hidden medulloblastoma cells. <i>Cancer Cell</i> , <b>2021</b> , 39, 1452-1454   | 24.3 |   |